Results 201 to 210 of about 37,430 (216)

Lenalidomide

Reactions Weekly, 2008
openaire   +1 more source

Lenalidomide enhances anti-myeloma cellular immunity

Cancer Immunology, Immunotherapy, 2012
Jacalyn Rosenblatt, Jeffrey I Zwicker, David Avigan   +2 more
exaly  

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

Leukemia, 2013
V Baladandayuthapani, J J Shāh, D M Weber   +2 more
exaly  

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide

Clinical Pharmacokinetics, 2016
Maria Palmisano, Simon Zhou, Nianhang Chen   +2 more
exaly  

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Microvascular Research, 2005
Simon P Robinson, David Stirling, Keith Dredge   +2 more
exaly  

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Leukemia, 2012
Takumi Ito
exaly  

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy

British Journal of Haematology, 2007
Tomer M Mark, David Jayabalan, Ruben Niesvizky   +2 more
exaly  

Lenalidomide

Reactions Weekly, 2020
openaire   +1 more source

Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

OncoImmunology, 2016
Anthony Ho, Dirk Hose, Hartmut Goldschmidt   +2 more
exaly  

Kidney dysfunction during lenalidomide treatment for AL amyloidosis.

Nephrology Dialysis Transplantation, 2011
Vaishali Sanchorawala, Laura M Dember, Anthony C Shelton   +2 more
exaly